Key Takeaways
- Shares of Cooper Companies plunged over 15% following the announcement that it would retain CooperSurgical, its women’s health and fertility division, terminating sale expectations.
- Third-quarter revenue reached $1.07 billion, falling short of the $1.10 billion analyst consensus.
- The company reduced its full-year adjusted EPS outlook to $4.51-$4.55 from the previous range of $4.58-$4.66.
- Annual revenue projections were lowered to $4.23-$4.25 billion, compared to earlier estimates of $4.29-$4.32 billion.
- CooperVision’s Q3 revenue declined to $717 million from $723.5 million sequentially, impacted by intentional U.S. inventory drawdowns.
Shares of Cooper Companies (COO) tumbled more than 15% during Thursday’s premarket session after the medical device manufacturer announced two significant setbacks: below-consensus quarterly revenue and the unexpected choice to maintain ownership of its CooperSurgical division.
The Cooper Companies, Inc., COO
Investor expectations had centered around a possible divestiture of CooperSurgical, the firm’s women’s health and fertility segment. However, following a comprehensive strategic evaluation concluded on Wednesday evening, Cooper’s board reached a unanimous decision to keep the business unit.
This announcement independently triggered substantial selling pressure. COO emerged as the most significant decliner within the S&P 500 during Thursday’s premarket session.
Regarding financial performance, Cooper exceeded adjusted earnings per share projections, reporting $1.15 versus the anticipated $1.12. However, topline results disappointed. Third-quarter revenue registered at $1.07 billion, undershooting the $1.10 billion Wall Street consensus.
The revenue miss stemmed primarily from an intentional drawdown of U.S. distributor inventory within its CooperVision contact lens segment, a tactical decision connected to the ongoing strategic evaluation.
CooperVision generated Q3 revenue of $717 million during the period concluded July 31, representing a sequential decline from $723.5 million in the preceding quarter.
Revised Outlook Intensifies Selling Pressure
Cooper additionally reduced its full-year projections. The adjusted EPS forecast was downgraded to $4.51-$4.55, contrasting with the earlier guidance of $4.58-$4.66. The analyst community had anticipated $4.63 per share.
Annual revenue expectations were similarly revised downward, now projected at $4.23-$4.25 billion against the previous outlook of $4.29-$4.32 billion. Analyst estimates had centered on $4.31 billion.
Looking ahead to Q4, Cooper provided guidance calling for revenue between $1.06-$1.08 billion and adjusted EPS ranging from $1.05-$1.09.
Management indicated that inventory challenges affecting Q3 performance are anticipated to persist throughout the fourth quarter.
Analyst Commentary
KeyBanc analyst Brett Fishbin suggested that investors would require time to digest the dual impact of reduced guidance alongside the strategic review’s conclusion without a transaction. His rating on the stock remains at Sector Weight.
A CooperSurgical divestiture had been viewed by market participants as a potential pathway toward establishing a focused contact lens entity, potentially attracting strategic buyers. With that scenario now off the table, the investment thesis faces reevaluation.
Cooper disclosed that it expanded its share buyback authorization to $3 billion from $2 billion.
The company holds the position as the world’s second-largest contact lens producer, trailing Johnson and Johnson’s Acuvue franchise.
Ongoing inventory normalization within the U.S. contact lens distribution channel represents the primary operational challenge as the company approaches the conclusion of fiscal 2026.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
